US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
イギリス
LSE
Aim Immunotech Inc (0A4Y)
Aim Immunotech Inc (0A4Y) ニュース

0A4Y

Aim Immunotech (0A4Y)

Aim Immunotech Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0A4Y

1

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/09	21 : 50	UK Regulatory	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	LSE:0A4Y	Aim Immunotech Inc
2024/05/06	21 : 30	UK Regulatory	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	LSE:0A4Y	Aim Immunotech Inc
2024/04/29	21 : 55	UK Regulatory	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc
2024/04/10	21 : 21	UK Regulatory	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	LSE:0A4Y	Aim Immunotech Inc
2024/04/02	20 : 30	UK Regulatory	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	LSE:0A4Y	Aim Immunotech Inc
2024/03/26	22 : 05	UK Regulatory	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	LSE:0A4Y	Aim Immunotech Inc
2024/03/25	22 : 05	UK Regulatory	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	LSE:0A4Y	Aim Immunotech Inc
2024/03/07	22 : 45	UK Regulatory	AIM ImmunoTech Announces Launch of CEO Corner Platform	LSE:0A4Y	Aim Immunotech Inc
2024/02/29	22 : 45	UK Regulatory	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update	LSE:0A4Y	Aim Immunotech Inc
2024/02/14	22 : 55	UK Regulatory	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc

Showing the most relevant articles for your search:LSE:0A4Y

1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約